Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of GZR4 Injection at Different Sites in Healthy Subjects
NCT06548906Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GZR4 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Area Under the Curve from time 0 to 672 hours. Started May 2024; status: recruiting.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06548906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548906.